A

    Adaptive Biotechnologies Corp (ADPT)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $24.23
    -0.19 (-0.78%)

    Market Cap: $3.90B

    Last updated: Sep 10, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    86%(25/29)
    Avg Surprise
    +12.51%
    Streak
    11 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.11 - $-0.08
    7 analysts
    EPS Revisions
    7
    0
    7d
    7
    0
    30d
    EPS Estimate Drift
    90d ago$-0.11-15.1%
    60d ago$-0.11-18.6%
    30d ago$-0.11-18.6%
    7d ago$-0.11-17.1%
    Current$-0.10
    Revenue Consensus
    $72M
    Range$70M - $73M
    7 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.17 - $-0.12
    7 analysts
    Revenue Consensus
    $95M
    Range$93M - $99M
    8 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.10---
    Jun 26
    Reported Jul 28
    		$-0.10$-0.13+23.08%Beat+41.2%
    Mar 26
    Reported May 5
    		$-0.13$-0.16+18.75%Beat+35.0%
    Dec 25
    Reported Feb 5
    		$-0.09$-0.18+50.00%Beat+60.9%
    Sep 25
    Reported Nov 5
    		$-0.15$-0.16+6.25%Beat+31.8%
    Jun 25
    Reported Aug 5
    		$-0.17$-0.24+29.17%Beat+41.4%
    Mar 25
    Reported May 1
    		$-0.20$-0.31+35.48%Beat+37.5%
    Dec 24
    Reported Feb 11
    		$-0.23$-0.24+4.17%Beat+23.3%
    Sep 24
    Reported Nov 7
    		$-0.22$-0.27+18.52%Beat+37.1%
    Jun 24
    Reported Aug 1
    		$-0.29$-0.33+12.12%Beat+12.1%
    Mar 24
    Reported May 7
    		$-0.32$-0.34+5.88%Beat+20.0%
    Dec 23
    Reported Feb 14
    		$-0.30$-0.33+9.09%Beat-7.1%
    Sep 23
    Reported Nov 9
    		$-0.35$-0.34-2.94%Miss-9.4%
    Jun 23
    Reported Aug 2
    		$-0.33$-0.35+5.71%Beat+10.8%
    Mar 23
    Reported May 3
    		$-0.40$-0.37-8.11%Miss+9.1%
    Dec 22
    Reported Feb 14
    		$-0.28$-0.35+20.00%Beat+34.9%
    Sep 22
    Reported Nov 3
    		$-0.32$-0.38+15.79%Beat+20.0%
    Jun 22
    Reported Aug 3
    		$-0.37$-0.43+13.95%Beat-5.7%
    Mar 22
    Reported May 4
    		$-0.44$-0.45+2.22%Beat-51.7%
    Dec 21
    Reported Feb 15
    		$-0.43$-0.45+4.44%Beat-30.3%
    Sep 21
    Reported Nov 3
    		$-0.40$-0.43+6.98%Beat-48.1%
    Jun 21
    Reported Aug 4
    		$-0.35$-0.41+14.63%Beat-34.6%
    Mar 21
    Reported May 5
    		$-0.29$-0.40+27.50%Beat-16.0%
    Dec 20
    Reported Feb 24
    		$-0.33$-0.29-13.79%Miss-94.1%
    Sep 20
    Reported Nov 10
    		$-0.27$-0.28+3.57%Beat-145.5%
    Jun 20
    Reported Aug 10
    		$-0.26$-0.28+7.14%Beat-100.0%
    Mar 20
    Reported May 12
    		$-0.25$-0.21-19.05%Miss-38.9%
    Dec 19
    Reported Feb 26
    		$-0.17$-0.20+15.00%Beat-
    Sep 19
    Reported Nov 12
    		$-0.11$-0.22+50.00%Beat-
    Jun 19
    Reported Aug 13
    		$-0.13$-0.14+7.14%Beat-
    Mar 19
    Reported Jun 27
    		$-0.18$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-51.55EV/EBITDA-1.00x
    Price/FCF-161.16xFCF Yield-0.62%
    Profitability
    Profit Margin-20.70%Operating Margin-22.00%
    ROE-38.80%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-1.06x
    Current Ratio4.79xQuick Ratio4.68x
    Trading Statistics
    Beta2.10Avg Volume1.70M
    52-Week High$26.8752-Week Low$12.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$24.74
    SMA 20$25.04
    SMA 50$23.65
    SMA 200$17.82
    EMA 10$24.64
    EMA 20$24.67
    EMA 50$23.26
    EMA 200$18.41

    MACD

    Line: 0.21Signal: 0.49Hist: -0.29

    ADX

    ADX: 21.8+DI: 14.0-DI: 20.1

    Aroon & PSAR

    Aroon Up64.0
    Aroon Down4.0
    PSAR$26.14

    Bollinger Bands

    Upper Band$26.49
    Lower Band$23.59
    %B Position1155%(Upper)
    Band Width0.22

    RSI (14-Day)

    Neutral
    48.0

    Momentum Oscillators

    Stoch %K22.6
    Stoch %D21.1
    Williams %R-79.0
    ROC (10d)-7.4%
    Momentum-1.93
    CCI (20d)-95.8
    MFI (14d)41.9

    Volatility Measures

    ATR (14d)$1.12(4.6%)
    StdDev (20d)0.72
    Hist Vol31.5%(Moderate)

    Volume Flow

    VWAP$24.14
    OBV70.7M
    AD Line43.6M
    CMF (20d)0.028

    Volume Metrics

    Avg Vol (20d)1.7M
    Vol Ratio0.6x
    VWMA (20d)$25.06

    Pivot Points

    R3$25.56
    R2$25.12
    R1$24.77
    Pivot Point$24.33
    S1$23.98
    S2$23.54
    S3$23.19

    Advanced Oscillators

    TSI6.34
    Ultimate Osc53.3
    KST56.82

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$71.55M$70.87M$71.68M$93.97M$58.88M$52.44M$47.46M$46.44M$43.19M$41.87M$45.78M$37.92M
    Cost of Revenue$20.16M$18.71M$18.22M$18.16M$18.00M$16.98M$18.05M$16.67M$19.32M$18.05M$19.62M$19.35M
    Gross Profit$51.39M$52.17M$53.46M$75.82M$40.88M$35.46M$29.41M$29.77M$23.87M$23.82M$26.17M$18.57M
    Operating Expenses$67.16M$71.37M$66.23M$65.53M$65.92M$65.07M$63.25M$62.40M$71.19M$72.58M$97.24M$69.53M
    R&D$19.15M$23.62M$21.76M$23.67M$24.13M$24.20M$23.19M$24.16M$25.35M$30.25M$28.75M$28.53M
    SG&A$21.17M$20.98M$19.56M$17.96M$17.79M$17.40M$18.06M$17.26M$17.89M$19.60M$20.73M$20.07M
    Operating Income$-15,770,000$-19,206,000$-12,773,000$10.29M$-25,036,000$-29,604,000$-33,837,000$-32,632,000$-47,318,000$-48,762,000$-71,068,000$-50,956,000
    Interest Income$2.26M$2.08M$2.15M$2.23M$2.39M$2.68M$3.07M$3.47M$3.77M$4.22M$4.61M$4.28M
    Interest Expense$26.43M$2.89M$2.95M$2.97M$2.95M$2.90M$2.95M$2.94M$2.70M$2.99M$3.01M$3.65M
    Income Before Tax$-39,941,000$-20,015,000$-13,579,000$9.54M$-25,593,000$-29,830,000$-33,717,000$-32,097,000$-46,248,000$-47,533,000$-69,467,000$-50,326,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-39,941,000$-20,015,000$-13,579,000$9.54M$-25,593,000$-29,830,000$-33,717,000$-32,097,000$-46,248,000$-47,533,000$-69,467,000$-50,326,000
    EBITDA$-12,187,000$-15,505,000$-8,866,000$14.18M$-21,284,000$-25,831,000$-30,847,000$-30,049,000$-44,414,000$-46,191,000$-68,635,000$-47,891,000
    EBIT$-15,770,000$-19,206,000$-12,773,000$10.29M$-25,036,000$-29,604,000$-33,837,000$-32,632,000$-47,318,000$-48,762,000$-71,068,000$-50,956,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ADPT

    Government Contracts

    Gov Obligations (TTM)
    $251000
    Gov Obligations / Revenue
    0.1%
    Obligations YoY
    N/A
    Active Awards
    9
    New Awards (TTM)
    2
    Avg Remaining Term
    6.4 mo

    Top agency: Department of Defense at 50.8% of trailing twelve month obligations across 2 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C25026P0251Department of Veterans AffairsDepartment of Veterans Affairs$243750Dec 29, 2025
    36C24126N0614Department of Veterans AffairsDepartment of Veterans Affairs$35100Jul 15, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    Adaptive Biotechnologies director Owen sells $249,990 in stock. By Investing.com

    Katey Einterz Owen, a director at Adaptive Biotechnologies Corp (ADPT), sold 9,615 shares of company stock for $249,990 on August 26, 2026, when the stock was near its 52-week high after an 89% gain. InvestingPro analysis indicates the stock may be overvalued. This sale occurred despite recent positive analyst sentiment and strong Q2 revenue, though the company missed adjusted EPS estimates.

    Investing.com Nigeria•8/28/26•
    Neutral

    Adaptive Biotechnologies stock hits 52-week high at $26.63

    Adaptive Biotechnologies (ADPT) stock recently hit a 52-week high of $26.63, reflecting a 1-year total return of 101.7%. Despite this strong performance, InvestingPro analysis suggests the stock might be overvalued at its current $4.18 billion market capitalization. The company reported a mixed Q2, with an adjusted loss per share wider than estimates but revenue exceeding expectations, driven by a 49% year-over-year growth in its core minimal residual disease business.

    Investing.com•8/27/26•
    Bullish

    Adaptive Biotechnologies director Robert Hershberg sells $748k in shares

    Robert Hershberg, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 30,664 shares of the company's common stock for a total of $748,208 on August 18, 2026. These sales occurred after Hershberg exercised stock options to acquire 15,000 shares. The company recently reported mixed Q2 results with revenue exceeding estimates, and BTIG and Guggenheim have raised their price targets on ADPT shares.

    Investing.com•8/21/26•
    Neutral

    Adaptive Biotechnologies director Robert Hershberg sells $748k in shares

    Robert Hershberg, a director at Adaptive Biotechnologies Corp (NASDAQ:ADPT), sold 30,664 shares totaling $748,208 on August 18, 2026. These sales occurred after Hershberg acquired 15,000 shares through option exercises at a much lower price. The stock's current valuation appears overvalued according to InvestingPro, despite a 107% return over the past year and recent positive analyst ratings.

    Investing.com•8/21/26•
    Somewhat-Bearish

    Bank of America Corp DE Acquires 421,645 Shares of Adaptive Biotechnologies Corporation $ADPT

    Bank of America Corp DE has increased its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 52.3% in the first quarter, acquiring an additional 421,645 shares and bringing its total holdings to 1,227,917 shares valued at $17,043,000. This comes amidst mixed sentiment for ADPT, with analysts maintaining a "Moderate Buy" consensus and significant institutional ownership, yet the company reported a quarterly EPS miss and experienced notable insider selling.

    MarketBeat•8/21/26•
    Neutral

    Frequently Asked Questions About ADPT

    Does ADPT pay dividends?
    Adaptive Biotechnologies Corp (ADPT) does not currently pay a regular dividend.
    What is ADPT's market cap?
    Adaptive Biotechnologies Corp (ADPT) has a market capitalization of $3.90B with a current stock price of $24.23.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In